Altimmune’s single dose, intranasal COVID-19 vaccine candidate prevented SARS-CoV-2-induced disease
On Mar. 15, 2021, Altimmune announced additional preclinical data for its single dose intranasal COVID-19 vaccine candidate, AdCOVID….
-
-
Biotechnology | CDC | COVID-19 | Diagnostics | Genomics | Infectious Disease | Vaccine
Fulgent Genetics awarded contract from CDC to study variants of COVID-19 virus
On Mar. 15, 2021, Fulgent Genetics announced that the U.S. Centers for Disease Control and Prevention had awarded…
-
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Therapeutics | Vaccine | WHO
WHO added Janssen vaccine to list of safe and effective emergency tools against COVID-19
On Mar. 12, 2021, The World Health Organization (WHO) listed the COVID-19 vaccine Ad26.COV2.S, developed by Janssen (Johnson…
-
Abbott announced Pandemic Defense Coalition to help prevent future pandemics
On Mar. 11, 2021, Abbott announced the formation of the Abbott Pandemic Defense Coalition, a first-of-its-kind global scientific…
-
ImmunityBio announced novel ACE2 decoy COVID-19 therapeutic that showed high binding to SARS-CoV-2 variants
On Mar. 11, 2021, ImmunityBio announced it was developing a novel hAd5 ACE2 Decoy therapeutic vaccine to neutralize…
-
Altimmune expanded AdCOVID manufacturing collaboration with Lonza
On Mar. 11, 2021, Altimmune announced that it had expanded its previously-announced AdCOVID manufacturing collaboration with Lonza. Under the…
-
Novavax confirmed ligh levels of efficacy against original and variant COVID-19 strains in UK and South Africa trials
On Mar. 11, 2021, Novavax announced final efficacy of 96.4% against mild, moderate and severe disease caused by…
-
Johnson & Johnson announced single-shot COVID-19 vaccine candidate received positive CHMP opinion
On Mar. 11, 2021, Johnson & Johnson announced that the Committee for Medicinal Products for Human Use (CHMP)…
-
Johnson & Johnson single-shot COVID-19 vaccine granted conditional Marketing Authorization by EC
On Mar. 11, 2021, Johnson & Johnson announced that the European Commission (EC) had granted a Conditional Marketing…
-
Real-world evidence confirmed high effectiveness of Pfizer-BioNTech COVID-19 vaccine
On Mar. 11, 2021, the Israel Ministry of Health (MOH), Pfizer and BioNTech announced real-world evidence demonstrating dramatically…
-
The U.S. Department of Defense identified more troops to help administer COVID-19 vaccine
On Mar. 10, 2021, the U.S. Department of Defense (DOD) announced that it had identified additional personnel authorized…
-
CEPI and VBI Vaccines collaborated to advance vaccine candidates against COVID-19 variants
On Mar. 10, 2021, CEPI, the Coalition for Epidemic Preparedness Innovations, and VBI Vaccines announced a partnership to…
-
Thermo Fisher Scientific announced $600 million in capital investments to expand its bioprocessing production
On Mar. 10, 2021, Thermo Fisher Scientific announced more than $600 million in capital investments to expand its…
-
Oragenics announced Material Transfer Agreement with Biodextris for mucosal adjuvant for intranasal COVID-19 vaccine
On Mar. 9, 2021, Oragenics announced it had entered into a material transfer agreement with Biodextris for the…
-
VBI Vaccines announced enrollment in adaptive phase 1/2 study of prophylactic COVID-19 vaccine candidate
On Mar. 9, 2021, VBI Vaccines announced the initiation of enrollment of its Phase 1/2 clinical study of…
-
Luminex submitted joint SARS-CoV-2 and Flu/RSV respiratory panel to FDA for Emergency Use Authorization
On Mar. 10, 2021, Luminex announced that it had submitted an Emergency Use Authorization application to the U.S….
-
AXIM Biotechnologies successfully completed point-of-care clinical trials on rapid COVID-19 antibody test
On Mar. 8, 2021, AXIM Biotechnologies announced that it had successfully completed point-of-care clinical trials on its much…
-
ImmunityBio and NantKwest began dosing participants in global trials for novel COVID-19 vaccine
On Mar. 8, 2021, ImmunityBio and NantKwest announced that the first cohorts of their South Africa and U.S….
-
AIM ImmunoTech announced first healthy subjects dosed in phase 1 intranasal Ampligen clinical study
On Mar. 8, 2021, AIM ImmunoTech announced that it had dosed the first healthy subjects in its Phase…
-
Baxter and Moderna announced agreement for manufacturing of Moderna COVID-19 vaccine in the US
On Mar. 8, 2021, Baxter and Moderna announced that they had entered into an agreement for Baxter BioPharma…
-
Moderna announced supply agreement to provide 13 million doses of COVID-19 vaccine to the Philippines
On Mar. 6, 2021, Moderna announced a supply agreement with the Government of The Philippines for 13 million doses…
-
Moderna announced NDA submitted to import and distribute Moderna’s COVID-19 vaccine candidate in Japan
On Mar. 5, 2021,Takeda Pharmaceutical announced that it has submitted a New Drug Application to the Government of…
-
Soligenix announced positive progress in pre-clinical development of its COVID-19 vaccine
On Mar. 4, 2021, Soligenix announced publication of pre-clinical immunogenicity studies for CiVax (heat stable COVID-19 vaccine program)…
-
Washington State Department of Health provided next-generation genome sequencing
On Mar. 4, 2021, the Washington State Department of Health announced contracts with virology labs at the University…
-
New evidence COVID-19 antibodies, vaccines less effective against variants
On Mar. 4, 2021, researchers at the University School of Medicine in St. Louis announced that three new,…
-
MediciNova announced it had discontinued development of a SARS-CoV-2 vaccine for COVID-19
On Mar. 3, 2021, MediciNova announced an update on the development of a SARS-CoV-2 vaccine for COVID-19. MediciNova…
-
Pfizer-BioNTech’s COVID-19 vaccine arrived in Rwanda
On Mar. 3, 2021, Pfizer and BioNTech, in partnership with UNICEF, announced the arrival of the first doses…
-
COVAX published first round of allocations
On Mar. 2, 2021, The Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance and the WHO,…
-
Merck announced partnership to produce Johnson & Johnson’s COVID-19 vaccine
On Mar. 2, 2021, Merck announced multiple agreements to support efforts to expand manufacturing capacity and supply of…
-
Biden administration announced collaboration between Merck and Johnson & Johnson to expand production of COVID-19 vaccines
On Mar. 2, 2021, Biden invoked the Defense Production Act to equip two Merck facilities to the standards necessary…
